Yahoo! (YHOO) 28.73 -3.87 (-11.9%) Internet company defies the Street's whisper numbers that called for Q2 (June) upside, and instead merely meets profit expectations ($0.08) and misses sales expectations ($609.1 mln versus the consensus of $611.7 mln); Management's Q3 (Sept) and FY04 (Dec) revenues guidance was similarly lackluster (weighted towards the low-end of estimates); Outlook and report has raised concerns about Yahoo!'s position ahead of Google's IPO; Other internet portals (AMZN, MAMA, LOOK, EBAY) have taken a hit
Siebel Systems (SEBL) 7.77 -1.44 (-15.6%) Software maker warns for Q2 (June) - following in the footsteps of PeopleSoft (PSFT) today, and JDA Software (JDAS) and Veritas (VRTS) yesterday; Siebel said the shortfall was due to delayed purchases on the part of several customers; Company now expects software license revenues to be about $95 mln, which it dubbed 'disappointing;' The entire software space is weak again tonight despite its pullback over the past 2 sessions
Alcoa (AA) 31.79 -0.98 (-3.0%) World's largest aluminum maker falls short of Wall Street's Q2 (June) estimates despite a large increase in aluminum prices - the second quarter in which this has happened; Alcoa reported a 70% increase in EPS, to $0.46 (consensus of $0.48), and an 11% rise in revenues, to $6.09 bln (consensus of $6.11 bln); Investors have taken profits from AA's 9% advance since early May as the company's miss suggests execution problems
Genentech (DNA) 55.18 +1.28 (+2.4%) Biotech giant matches the Reuters Estimates EPS consensus of $0.19 on revenues that jumped 41% to $1.13 bln (consensus $1.065 bln) in its Q2 (June) report; Genentech goes on to top the Street's forecasts in 3 out of its 4 major drugs; Company now expects FY04 (Dec) EPS to rise 25-33% (versus 20-25% earlier) to $0.75-0.80 (consensus of $0.79); Briefing.com has recommended DNA as a play on the biotech space for over a year now - in response to its approval of colon cancer drug Avastin
O Clubeinvest.com informa que nenhuma da informação
aqui facultada deverá ser entendida como conselho ou recomendação
de qualquer tipo de transacção ou investimento.
